Hester BiosQ4 FY24

Hester Bios Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹2,324.6P/E: 33.7Market Cap: ₹2.0K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3
  • The poultry industry is on an upswing, leading to increased vaccine uptake as farmers adopt more progressive farming methods.
  • Animal healthcare industry growth is expected around 8%-9%, with Hester Biosciences targeting 12% standalone growth.
  • For FY25 and beyond, the company aims to improve both topline (sales/revenue) and bottomline (profitability), working hard to capitalize on market recovery and election year demand.
  • The African subsidiary loss is expected to improve with gradual market normalization, enabling better order fulfillment and revenue generation.
  • New product introductions in therapeutics, supplements, pet food diet segments, and specialized poultry products are anticipated to contribute to growth.
  • The BSL-3 facility and fill-finish line are nearing commercialization, expected to enhance manufacturing capacity and sales in the near term.
  • Distribution network expansion and improved after-sales monitoring aim to strengthen market position and volume growth.

See what Hester Bios management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • There is no mention of any current or planned fundraising through debt or equity in the transcript.
  • Rajiv Gandhi and other management representatives referred to debt repayment, indicating existing debt reduction efforts (e.g., Rs. 25-30 crores being paid annually, and Rs. 30 crores debt reduced recently).
  • Management emphasized focusing on improving profitability and operational performance rather than new fundraising.
  • No explicit plans or discussions about raising fresh capital via debt or equity were disclosed during the call.

See what Hester Bios management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Rs. 168 crores of capital work-in-progress primarily related to:
  • - BSL-3 facility at Hester India plant (originally for COVID vaccine production, now being repurposed for veterinary vaccines).
  • - Fill-finish line, expected to be commercially operational within the next two months.
  • Completed receipt of all government grants for building BSL-3 facility; no pending grants.
  • Repurposing BSL-3 facility for commercial production of veterinary vaccines to enhance manufacturing capacity.
  • Active steps to introduce new products in therapeutics, supplements, prescription, and pet food diet segments to diversify offerings.
  • Strategic focus on strengthening presence in African veterinary markets with dossiers submitted for additional products (CCPP and Sheep and Goat Pox).
  • Ongoing efforts to build a robust marketing network in East and Central Africa to support growth.
  • Investment aimed at expanding capacities and market reach, signaling commitment to sustained growth.

Track Hester Bios — get its next earnings analysis in your feed

How does Hester Bios rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisHester Bios
Rev 3Mar 3

How does Hester Bios rank in Pharmaceuticals & Biotechnology?

Compare Hester Bios against every Pharmaceuticals & Biotechnology company (Q4 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →